MARIA TSAO: Open Payments
NPI 1336257278 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,851 in 75 payments from 10 companies in 2025. Trend: 2023 $2,527 · 2024 $2,568 · 2025 $2,851
Food & beverage: $2,851
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $596 |
| Vanda Pharmaceuticals Inc. | 11 | $477 |
| Otsuka America Pharmaceutical, Inc. | 15 | $419 |
| E.R. Squibb & Sons, L.L.C. | 6 | $309 |
| Neurocrine BioSciences, Inc. | 11 | $293 |
| ABBVIE INC. | 7 | $280 |
| Alkermes, Inc. | 7 | $170 |
| Janssen Pharmaceuticals, Inc | 5 | $150 |
| Axsome Therapeutics, Inc. | 1 | $119 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
Products named: CAPLYTA, FANAPT, COBENFY, INGREZZA, ABILIFY MAINTENA, VRAYLAR, INVEGA SUSTENNA, HETLIOZ.
Industry payments across VA — which companies pay providers there.
